In Du Jeong1, Seok Won Jung1, Bo Ryung Park2, Byung Uk Lee1, Jae Ho Park1, Byung Gyu Kim1, Sung-Jo Bang1, Jung Woo Shin1, Neung Hwa Park3,4. 1. Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, 887 Bangeojinsunhwando-ro, Dong-gu, Ulsan, 44033, Republic of Korea. 2. Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea. 3. Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, 887 Bangeojinsunhwando-ro, Dong-gu, Ulsan, 44033, Republic of Korea. nhpark@uuh.ulsan.kr. 4. Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea. nhpark@uuh.ulsan.kr.
Abstract
BACKGROUND/AIMS: The clinical course of chronic hepatitis B (CHB) patients with partial virologic response (PVR) during tenofovir disoproxil fumarate (TDF) therapy remains unclear. METHODS: We retrospectively investigated the long-term clinical outcomes of TDF treatment in nucleos(t)ides-naïve CHB patients, particularly in those with PVR. RESULTS: A total of 391 patients treated with TDF therapy for more than 12 months were included. Virologic response (VR) was achieved in 341 patients (87.2%). PVR was evident in 127 (45.3%) of the 391 patients. Multivariate logistic regression analysis using selected baseline factors identified absolute HBV DNA levels at baseline (OR 0.496; 95% CI 1.369-1.969) and HBeAg positivity (OR 0.622; 95% CI 1.096-3.167) as factors significantly associated with PVR. During continuous prolonged TDF therapy, 127 (71.8%) of 177 patients with PVR achieved VR. The cumulative rates of VR in patients with PVR at 12, 24, and 36 months were 42.4, 79.7, and 90.2%, respectively. Serum HBV DNA level at week 24 was significantly associated with VR in patients with PVR. CONCLUSIONS: The vast majority of CHB patients with PVR achieved VR through prolonged TDF therapy, although the time to achieve VR was delayed in those with PVR. This suggests that adjustment of TDF therapy in patients with PVR is unnecessary.
BACKGROUND/AIMS: The clinical course of chronic hepatitis B (CHB) patients with partial virologic response (PVR) during tenofovir disoproxil fumarate (TDF) therapy remains unclear. METHODS: We retrospectively investigated the long-term clinical outcomes of TDF treatment in nucleos(t)ides-naïve CHB patients, particularly in those with PVR. RESULTS: A total of 391 patients treated with TDF therapy for more than 12 months were included. Virologic response (VR) was achieved in 341 patients (87.2%). PVR was evident in 127 (45.3%) of the 391 patients. Multivariate logistic regression analysis using selected baseline factors identified absolute HBV DNA levels at baseline (OR 0.496; 95% CI 1.369-1.969) and HBeAg positivity (OR 0.622; 95% CI 1.096-3.167) as factors significantly associated with PVR. During continuous prolonged TDF therapy, 127 (71.8%) of 177 patients with PVR achieved VR. The cumulative rates of VR in patients with PVR at 12, 24, and 36 months were 42.4, 79.7, and 90.2%, respectively. Serum HBV DNA level at week 24 was significantly associated with VR in patients with PVR. CONCLUSIONS: The vast majority of CHB patients with PVR achieved VR through prolonged TDF therapy, although the time to achieve VR was delayed in those with PVR. This suggests that adjustment of TDF therapy in patients with PVR is unnecessary.
Authors: Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote Journal: Lancet Date: 2012-12-10 Impact factor: 79.321
Authors: Nghiem B Ha; Nghi B Ha; Ruel T Garcia; Huy N Trinh; Kevin T Chaung; Huy A Nguyen; Khanh K Nguyen; Brian S Levitt; Mindie H Nguyen Journal: Dig Dis Sci Date: 2011-02-17 Impact factor: 3.199
Authors: J W Shin; S W Jung; B R Park; C J Kim; J B Eum; B G Kim; I D Jeong; S-J Bang; S-H Lee; S R Kim; N H Park Journal: J Viral Hepat Date: 2012-03-15 Impact factor: 3.728
Authors: S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao Journal: Hepatol Int Date: 2015-11-13 Impact factor: 6.047
Authors: Roeland Zoutendijk; Jurriën G P Reijnders; Ashley Brown; Fabien Zoulim; David Mutimer; Katja Deterding; Jörg Petersen; Wolf Peter Hofmann; Maria Buti; Teresa Santantonio; Florian van Bömmel; Pierre Pradat; Ye Oo; Marc Luetgehetmann; Thomas Berg; Bettina E Hansen; Heiner Wedemeyer; Harry L A Janssen Journal: Hepatology Date: 2011-08 Impact factor: 17.425